Logo image of COGT

COGENT BIOSCIENCES INC (COGT) Stock Fundamental Analysis

NASDAQ:COGT - Nasdaq - US19240Q2012 - Common Stock - Currency: USD

11.47  +0.54 (+4.94%)

Fundamental Rating

1

Overall COGT gets a fundamental rating of 1 out of 10. We evaluated COGT against 550 industry peers in the Biotechnology industry. While COGT seems to be doing ok healthwise, there are quite some concerns on its profitability. COGT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

COGT had negative earnings in the past year.
COGT had a negative operating cash flow in the past year.
In the past 5 years COGT always reported negative net income.
In the past 5 years COGT always reported negative operating cash flow.
COGT Yearly Net Income VS EBIT VS OCF VS FCFCOGT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M -250M

1.2 Ratios

With a Return On Assets value of -74.40%, COGT is not doing good in the industry: 66.36% of the companies in the same industry are doing better.
With a Return On Equity value of -131.89%, COGT is not doing good in the industry: 60.36% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -74.4%
ROE -131.89%
ROIC N/A
ROA(3y)-52.46%
ROA(5y)-51.99%
ROE(3y)-64.47%
ROE(5y)-60.7%
ROIC(3y)N/A
ROIC(5y)N/A
COGT Yearly ROA, ROE, ROICCOGT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

COGT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
COGT Yearly Profit, Operating, Gross MarginsCOGT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for COGT has been increased compared to 1 year ago.
Compared to 5 years ago, COGT has more shares outstanding
COGT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
COGT Yearly Shares OutstandingCOGT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
COGT Yearly Total Debt VS Total AssetsCOGT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -0.27, we must say that COGT is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.27, COGT is in the better half of the industry, outperforming 62.36% of the companies in the same industry.
A Debt/Equity ratio of 0.28 indicates that COGT is not too dependend on debt financing.
The Debt to Equity ratio of COGT (0.28) is worse than 72.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF N/A
Altman-Z -0.27
ROIC/WACCN/A
WACCN/A
COGT Yearly LT Debt VS Equity VS FCFCOGT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

COGT has a Current Ratio of 4.19. This indicates that COGT is financially healthy and has no problem in meeting its short term obligations.
COGT's Current ratio of 4.19 is in line compared to the rest of the industry. COGT outperforms 48.18% of its industry peers.
A Quick Ratio of 4.19 indicates that COGT has no problem at all paying its short term obligations.
COGT has a Quick ratio (4.19) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.19
Quick Ratio 4.19
COGT Yearly Current Assets VS Current LiabilitesCOGT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 17.92% over the past year.
EPS 1Y (TTM)17.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 18.02% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-9.57%
EPS Next 2Y-1.05%
EPS Next 3Y15.23%
EPS Next 5Y18.02%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
COGT Yearly Revenue VS EstimatesCOGT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
COGT Yearly EPS VS EstimatesCOGT Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for COGT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for COGT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
COGT Price Earnings VS Forward Price EarningsCOGT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
COGT Per share dataCOGT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as COGT's earnings are expected to grow with 15.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.05%
EPS Next 3Y15.23%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for COGT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COGENT BIOSCIENCES INC

NASDAQ:COGT (8/12/2025, 2:16:05 PM)

11.47

+0.54 (+4.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/bmo
Earnings (Next)08-12 2025-08-12/bmo
Inst Owners103.04%
Inst Owner Change0.8%
Ins Owners0.04%
Ins Owner Change0%
Market Cap1.60B
Analysts82.22
Price Target19.07 (66.26%)
Short Float %9.94%
Short Ratio4.28
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)21.43%
PT rev (3m)16.15%
EPS NQ rev (1m)5.93%
EPS NQ rev (3m)3.32%
EPS NY rev (1m)0%
EPS NY rev (3m)3.5%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 10.31
P/tB 10.31
EV/EBITDA N/A
EPS(TTM)-1.97
EYN/A
EPS(NY)-2.01
Fwd EYN/A
FCF(TTM)-1.68
FCFYN/A
OCF(TTM)-1.68
OCFYN/A
SpS0
BVpS1.11
TBVpS1.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -74.4%
ROE -131.89%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-52.46%
ROA(5y)-51.99%
ROE(3y)-64.47%
ROE(5y)-60.7%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.67%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.19
Quick Ratio 4.19
Altman-Z -0.27
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)321.08%
Cap/Depr(5y)421.98%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.86%
EPS Next Y-9.57%
EPS Next 2Y-1.05%
EPS Next 3Y15.23%
EPS Next 5Y18.02%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-22.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-4%
EBIT Next 3Y7.82%
EBIT Next 5YN/A
FCF growth 1Y-64.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-72.67%
OCF growth 3YN/A
OCF growth 5YN/A